Growth Metrics

Merck (MRK) Depreciation & Amortization (CF) (2016 - 2025)

Merck (MRK) has disclosed Depreciation & Amortization (CF) for 17 consecutive years, with $1.5 billion as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 186.02% to $1.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $3.0 billion, a 44.72% increase, with the full-year FY2025 number at $3.0 billion, up 44.72% from a year prior.
  • Depreciation & Amortization (CF) was $1.5 billion for Q4 2025 at Merck, up from $532.0 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.5 billion in Q4 2025 to a low of $371.0 million in Q2 2021.
  • A 5-year average of $518.9 million and a median of $486.5 million in 2022 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): plummeted 64.6% in 2021, then skyrocketed 186.02% in 2025.
  • Merck's Depreciation & Amortization (CF) stood at $430.0 million in 2021, then changed by 0.0% to $430.0 million in 2022, then grew by 16.74% to $502.0 million in 2023, then rose by 3.98% to $522.0 million in 2024, then surged by 186.02% to $1.5 billion in 2025.
  • Per Business Quant, the three most recent readings for MRK's Depreciation & Amortization (CF) are $1.5 billion (Q4 2025), $532.0 million (Q3 2025), and $518.0 million (Q2 2025).